Antibody drug conjugates: Development, characterization, and regulatory considerations
出版年份 2019 全文链接
标题
Antibody drug conjugates: Development, characterization, and regulatory considerations
作者
关键词
-
出版物
POLYMERS FOR ADVANCED TECHNOLOGIES
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2019-12-30
DOI
10.1002/pat.4789
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoids
- (2018) Thomas Nittoli et al. BIOORGANIC & MEDICINAL CHEMISTRY
- ADCT-402, a PBD dimer–containing antibody drug conjugate targeting CD19-expressing malignancies
- (2018) Francesca Zammarchi et al. BLOOD
- Modulation of Macropinocytosis-Mediated Internalization Decreases Ocular Toxicity of Antibody–Drug Conjugates
- (2018) Hui Zhao et al. CANCER RESEARCH
- Resistance to Antibody–Drug Conjugates
- (2018) Sara García-Alonso et al. CANCER RESEARCH
- FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
- (2018) Emily Y. Jen et al. CLINICAL CANCER RESEARCH
- Clinical and Histological Characterization of Toxic Keratopathy From Depatuxizumab Mafodotin (ABT-414), an Antibody–Drug Conjugate
- (2018) Brian A. Lee et al. CORNEA
- Investigational CD33-targeted therapeutics for acute myeloid leukemia
- (2018) Roland B. Walter EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy
- (2018) Hadi Nasiri et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Overview on natural hydrophilic polysaccharide polymers in drug delivery
- (2018) Fatemeh Abedini et al. POLYMERS FOR ADVANCED TECHNOLOGIES
- Target therapy: new drugs or new combinations of drugs in malignant pleural mesothelioma
- (2018) Paolo A. Zucali Journal of Thoracic Disease
- New Targets for the Treatment of Relapse and Refractory Multiple Myeloma
- (2018) Thomas Martin Clinical Lymphoma Myeloma & Leukemia
- A phase I expansion cohorts study of SYD985 in heavily pretreated patients with HER2-positive or HER2-low metastatic breast cancer.
- (2018) Cristina Saura et al. JOURNAL OF CLINICAL ONCOLOGY
- Transferrin-conjugated magnetic dextran-spermine nanoparticles for targeted drug transport across blood-brain barrier
- (2017) Maryam Ghadiri et al. JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
- Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
- (2017) Aditya Bardia et al. JOURNAL OF CLINICAL ONCOLOGY
- Characterization of Site-Specifically Conjugated Monomethyl Auristatin E– and Duocarmycin-Based Anti-PSMA Antibody–Drug Conjugates for Treatment of PSMA-Expressing Tumors
- (2017) Susanne Lütje et al. JOURNAL OF NUCLEAR MEDICINE
- Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
- (2017) Charles M Rudin et al. LANCET ONCOLOGY
- Strategies and challenges for the next generation of antibody–drug conjugates
- (2017) Alain Beck et al. NATURE REVIEWS DRUG DISCOVERY
- Antibody–drug conjugate directed against the guanylyl cyclase antigen for the treatment of gastrointestinal malignancies
- (2017) Khaldoun Almhanna et al. PHARMACOLOGY & THERAPEUTICS
- Comparison of a mouse and a novel human scFv-SNAP-auristatin F drug conjugate with potent activity against EGFR-overexpressing human solid tumor cells
- (2017) Mira Woitok et al. OncoTargets and Therapy
- Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma
- (2016) A. Viardot et al. BLOOD
- MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
- (2016) Margaret E. Whicker et al. BMC CANCER
- Antibody-drug conjugates—an emerging class of cancer treatment
- (2016) Nikolaos Diamantis et al. BRITISH JOURNAL OF CANCER
- Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer
- (2016) Jung-Min Lee et al. CLINICAL CANCER RESEARCH
- New developments for antibody-drug conjugate-based therapeutic approaches
- (2016) Bart ECG de Goeij et al. CURRENT OPINION IN IMMUNOLOGY
- First-in-human phase I trial of the anti-CEACAM5 antibody–drug conjugate SAR408701 in patients with advanced solid tumors (NCT02187848)
- (2016) A. Gazzah et al. EUROPEAN JOURNAL OF CANCER
- Folate receptor-targeted multimodal polymersomes for delivery of quantum dots and doxorubicin to breast adenocarcinoma: In vitro and in vivo evaluation
- (2016) Mona Alibolandi et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
- (2016) Heather Donaghy mAbs
- Tumor microenvironment and intracellular signal-activated nanomaterials for anticancer drug delivery
- (2016) Ran Mo et al. Materials Today
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
- (2016) Hagop M. Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Olaparib significantly delays photoreceptor loss in a model for hereditary retinal degeneration
- (2016) Ayse Sahaboglu et al. Scientific Reports
- Antibody-drug conjugates for cancer therapy: The technological and regulatory challenges of developing drug-biologic hybrids
- (2015) Gregory S. Hamilton BIOLOGICALS
- Antibody-drug conjugates as novel anti-cancer chemotherapeutics
- (2015) C. Peters et al. BIOSCIENCE REPORTS
- Autorisation de mise sur le marché du trastuzumab emtansine (Kadcyla®) dans les cancers du sein métastatiques HER2-positifs
- (2015) Mathilde Guerin et al. BULLETIN DU CANCER
- An emerging playbook for antibody–drug conjugates: lessons from the laboratory and clinic suggest a strategy for improving efficacy and safety
- (2015) Penelope M Drake et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Antibody-targeted drugs and drug resistance—Challenges and solutions
- (2015) LeeRon Shefet-Carasso et al. DRUG RESISTANCE UPDATES
- Antibody–Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs
- (2015) Christopher R. Behrens et al. MOLECULAR PHARMACEUTICS
- Organometallic palladium reagents for cysteine bioconjugation
- (2015) Ekaterina V. Vinogradova et al. NATURE
- Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index
- (2015) Robert P Lyon et al. NATURE BIOTECHNOLOGY
- Current ADC Linker Chemistry
- (2015) Nareshkumar Jain et al. PHARMACEUTICAL RESEARCH
- Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency
- (2015) Roger R. Beerli et al. PLoS One
- Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy
- (2014) Ravi V. J. Chari et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Engineered Nanoparticles for Drug Delivery in Cancer Therapy
- (2014) Tianmeng Sun et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Bridging Disulfides for Stable and Defined Antibody Drug Conjugates
- (2014) George Badescu et al. BIOCONJUGATE CHEMISTRY
- Regioselective and Stoichiometrically Controlled Conjugation of Photodynamic Sensitizers to a HER2 Targeting Antibody Fragment
- (2014) Francesca Bryden et al. BIOCONJUGATE CHEMISTRY
- Transglutaminase-Based Chemo-Enzymatic Conjugation Approach Yields Homogeneous Antibody–Drug Conjugates
- (2014) Patrick Dennler et al. BIOCONJUGATE CHEMISTRY
- Production of Site-Specific Antibody–Drug Conjugates Using Optimized Non-Natural Amino Acids in a Cell-Free Expression System
- (2014) Erik S. Zimmerman et al. BIOCONJUGATE CHEMISTRY
- Ligand-Directed Active Tumor-Targeting Polymeric Nanoparticles for Cancer Chemotherapy
- (2014) Yinan Zhong et al. BIOMACROMOLECULES
- Antibody–drug conjugates—A new wave of cancer drugs
- (2014) Hervé Bouchard et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Curative Properties of Noninternalizing Antibody-Drug Conjugates Based on Maytansinoids
- (2014) E. Perrino et al. CANCER RESEARCH
- Synthesis of AS1411-Aptamer-Conjugated CdTe Quantum Dots with High Fluorescence Strength for Probe Labeling Tumor Cells
- (2014) Mona Alibolandi et al. JOURNAL OF FLUORESCENCE
- Polymeric nanoparticles for therapy and imaging
- (2014) Wenjie He et al. POLYMERS FOR ADVANCED TECHNOLOGIES
- Polymers in gene therapy technology
- (2014) Hossein Hosseinkhani et al. POLYMERS FOR ADVANCED TECHNOLOGIES
- A general approach to site-specific antibody drug conjugates
- (2014) Feng Tian et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
- (2013) S. H. Petersdorf et al. BLOOD
- Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates
- (2013) Pavel Strop et al. CHEMISTRY & BIOLOGY
- Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies
- (2013) Miroslav Dostalek et al. CLINICAL PHARMACOKINETICS
- Antibody–drug conjugates: current status and future directions
- (2013) Heidi L. Perez et al. DRUG DISCOVERY TODAY
- Engineering of magnetic DNA nanoparticles for tumor-targeted therapy
- (2013) Hossein Hosseinkhani et al. JOURNAL OF NANOPARTICLE RESEARCH
- Milatuzumab-SN-38 Conjugates for the Treatment of CD74+ Cancers
- (2013) S. V. Govindan et al. MOLECULAR CANCER THERAPEUTICS
- Native Intact Mass Determination of Antibodies Conjugated with Monomethyl Auristatin E and F at Interchain Cysteine Residues
- (2012) John F. Valliere-Douglass et al. ANALYTICAL CHEMISTRY
- Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer
- (2012) Sandhya Girish et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Catabolic Fate and Pharmacokinetic Characterization of Trastuzumab Emtansine (T-DM1): an Emphasis on Preclinical and Clinical Catabolism
- (2012) Ben-Quan Shen et al. CURRENT DRUG METABOLISM
- The future of antibodies as cancer drugs
- (2012) Janice M. Reichert et al. DRUG DISCOVERY TODAY
- Cellular Delivery of Doxorubicin via pH-Controlled Hydrazone Linkage Using Multifunctional Nano Vehicle Based on Poly(β-L-Malic Acid)
- (2012) Rameshwar Patil et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
- (2012) Peter D Senter et al. NATURE BIOTECHNOLOGY
- Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
- (2012) Ben-Quan Shen et al. NATURE BIOTECHNOLOGY
- Brentuximab vedotin
- (2012) Anas Younes et al. NATURE REVIEWS DRUG DISCOVERY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preparation of unnatural N-to-N and C-to-C protein fusions
- (2012) Martin D. Witte et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Synthesis of site-specific antibody-drug conjugates using unnatural amino acids
- (2012) J. Y. Axup et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer
- (2011) P. M. LoRusso et al. CLINICAL CANCER RESEARCH
- Antibody Conjugate Therapeutics: Challenges and Potential
- (2011) B. A. Teicher et al. CLINICAL CANCER RESEARCH
- Synthesis and Evaluation of Hydrophilic Linkers for Antibody–Maytansinoid Conjugates
- (2011) Robert Y. Zhao et al. JOURNAL OF MEDICINAL CHEMISTRY
- Analytical methods for physicochemical characterization of antibody drug conjugates
- (2011) Aditya Wakankar et al. mAbs
- Pharma interest surges in antibody drug conjugates
- (2011) Sarah Webb NATURE BIOTECHNOLOGY
- Proteolytic networks in cancer
- (2011) Steven D. Mason et al. TRENDS IN CELL BIOLOGY
- Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components
- (2011) Franco Dosio et al. Toxins
- Integrating molecular diagnostics into anticancer drug discovery
- (2010) István Peták et al. NATURE REVIEWS DRUG DISCOVERY
- Monoclonal antibodies — a proven and rapidly expanding therapeutic modality for human diseases
- (2010) Zhiqiang An Protein & Cell
- Design, Synthesis, and Biological Evaluation of Antibody−Drug Conjugates Comprised of Potent Camptothecin Analogues
- (2009) Patrick J. Burke et al. BIOCONJUGATE CHEMISTRY
- Antibody−Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies
- (2009) Laurent Ducry et al. BIOCONJUGATE CHEMISTRY
- Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates
- (2008) Stephen C. Alley et al. BIOCONJUGATE CHEMISTRY
- A History of Cancer Chemotherapy
- (2008) Vincent T. DeVita et al. CANCER RESEARCH
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
- (2008) Jagath R Junutula et al. NATURE BIOTECHNOLOGY
- Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs
- (2007) Ravi V. J. Chari ACCOUNTS OF CHEMICAL RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started